Dr. Kohli on the SELECT Trial: Semaglutide Reduces MACE in Obese Patients With Heart Disease
By Payal Kohli, MD, FACC - Last Updated: August 24, 2023Novo Nordisk recently announced the headline results from the SELECT cardiovascular outcomes trial, which showed that semaglutide, a GLP-1 receptor agonist, reduces major adverse cardiovascular events in overweight or obese adults with cardiovascular disease.
Advertisement
DocWire News Medical Lead Dr. Payal Kohli talked about this landmark study and the impact of the findings on the cardiovascular community.
Post Tags:Cardiology Videos
Advertisement
Related Posts
Dr. Payal Kohli weighs in on Bronny James' cardiac arrest scare and what the event means for his future.
Dr. Payal Kohli talks about the dangerous association between air pollutants and cardiovascular events.
Dr. Payal Kohli talks about the how mental health impacts cardiovascular health, and vice versa.
Dr. Payal Kohli talks about the symptoms and dangers of meningitis, and whether or not it poses a public health threat.
Dr. Payal Kohli talks about Ray Romano's recent heart scare, as the actor had a 90% blockage in his "widow maker."
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.